文献速递膀胱癌与上尿路尿路上皮癌

体重指数对机器人辅助根治性膀胱切除术联合体内尿流改道的影响

Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion.
PubMed 文献 · BJU Int · 2017-07-27

本研究纳入2010年7月至2015年12月间接受机器人辅助根治性膀胱切除术、扩大淋巴结清扫及体内尿流改道的216例患者,按2004年世界卫生组织肥胖分类分为四组。结果显示肥胖患者出血量和手术时间增加,但住院时间、输血率、再入院率、90天总体及高级别并发症、复发无生存和总生存组间无显著差异。作者认为该术式在肥胖膀胱癌患者中安全可行。

要点

  • 肥胖组出血量和手术时间较非肥胖组增加(P=0.02和P=0.04)。
  • 住院时间、输血率、再入院率及90天并发症组间无显著差异。
  • 中位随访13个月,复发无生存和总生存组间无显著差异。

核心结论

  • 机器人辅助根治性膀胱切除术联合体内尿流改道在肥胖膀胱癌患者中安全可行。
  • 体重指数与围手术期、病理或早期肿瘤学结局的显著差异无关。

研究设计与样本

  • 回顾性纳入2010年7月至2015年12月间接受机器人辅助根治性膀胱切除术、扩大淋巴结清扫及体内尿流改道的216例患者。
  • 按2004年世界卫生组织肥胖分类分为四组:<25 kg/m2(正常)、25-29.9 kg/m2(超重前期)、30-34.9 kg/m2(肥胖I级)、≥35 kg/m2(肥胖II级)。
  • 使用SAS统计软件比较术前、术中、术后特征、肿瘤学结局及90天并发症。

主要发现

  • 全部216例均行体内尿流改道,其中68例(32%)行原位新膀胱构建。
  • 中位(范围)年龄71.8(35-95)岁,男性占80.6%,Charlson合并症指数评分0-1分者占66.2%。
  • 病理分期:原位癌至T2期占55.1%,T3-T4/N0期占18.5%,Tx/N+期占26.4%;中位(四分位距)淋巴结计数41(28,53)枚,阳性软组织切缘率4.2%。
  • 肥胖患者出血量更多、手术时间更长(P=0.02和P=0.04)。
  • 住院时间、输血率、再入院率、90天总体并发症率和高级别并发症率组间无显著差异(分别为P=0.16、P=0.96、P=0.89、P=0.22和P=0.51)。

临床怎么用

  • 原文结论认为机器人辅助根治性膀胱切除术联合体内尿流改道在肥胖膀胱癌患者中安全可行,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of body mass index (BMI) on peri-operative and oncological outcomes after robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion. PATIENTS AND METHODS: A total of 216 patients undergoing RARC, extended lymphadenectomy and intracorporeal urinary diversion, between July 2010 and December 2015, were categorized into four BMI groups according to the 2004 World Health Organization obesity classification groups: <25 kg/m2 (normal); 25-29.9 kg/m2 (pre-obese); 30-34.9 kg/m2 (obese class I); and ≥35 kg/m2 (obese class II). Pre-, intra- and postoperative characteristics, oncological outcomes, and 90-day complications were compared using sas statistical software. RESULTS: All 216 patients underwent intracorporeal urinary diversion, with 68 (32%) undergoing orthotopic neobladder construction. Demographics were similar among the BMI groups with regard to median (range) age (71.8 [35- 95] years), gender (80.6% men), Charlson comorbidity index (CCI) score (66.2% with CCI score 0-1), pathological stage (carcinoma in situ to T2: 55.1%, T3-T4/N0: 18.5%, Tx/N+: 26.4%), median (interquartile range) node count [41 (28, 53)] and positive soft tissue margin rate (4.2%). Obese patients had greater blood loss and longer operating time (P = 0.02 and P = 0.04, respectively). There were no significant differences in length of hospital stay, transfusion rates, readmission or 90-day overall and high-grade complication rates (P = 0.16, P = 0.96, P = 0.89, P = 0.22 and P = 0.51, respectively). At a median (range) follow-up of 13 months (15 days to 4.8 years), recurrence-free survival (P = 0.92) and overall survival (P = 0.68) were similar among the groups. CONCLUSION: The results of the present study show that RARC with intracorporeal urinary diversion is safe and feasible in obese patients with bladder cancer. BMI was not associated with significant differences in peri-operative, pathological or early oncological outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ahmadi N, Clifford TG, Miranda G, et al. Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion. BJU Int. 2017. PMID: 28544311. doi:10.1111/bju.13916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。